STOCK TITAN

Pulmatrix Inc - PULM STOCK NEWS

Welcome to our dedicated news page for Pulmatrix (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulmatrix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulmatrix's position in the market.

Rhea-AI Summary
Pulmatrix, Inc. reported $19.2 million in cash and cash equivalents at the end of 2023, ensuring cash runway until Q1 2026. The 3rd amendment to the Cipla partnership led to the cessation of the PUR1900 Phase 2b study, reducing cash burn. Cipla will now independently develop PUR1900, focusing on high-demand markets, with Pulmatrix receiving a 2% royalty on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Pulmatrix, Inc. (PULM) announces a further amendment to its agreement with Cipla for the development of PUR1900, refocusing on markets with the greatest unmet need and a faster path to approval. Cipla will take sole responsibility for the development of PUR1900, while Pulmatrix will significantly reduce cash burn and focus on strategic alternatives. Pulmatrix will receive 2% royalties on net sales of Pulmazole in the Cipla Territory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
partnership clinical trial
-
Rhea-AI Summary
Pulmatrix, Inc. (PULM) reports Q3 2023 results, with $21.3 million in cash and cash equivalents providing projected cash runway into Q1 2025. Phase 2b study of PUR1900 ongoing with 17 active sites in four countries, topline data expected in H2 2024. Received 'study may proceed' letter for Phase 2 study of PUR3100 for acute migraine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
earnings
Rhea-AI Summary
Pulmatrix receives FDA acceptance for PUR3100 IND application and study may proceed letter for Phase 2 study on acute migraine treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
clinical trial
-
Rhea-AI Summary
Results show low likelihood of drug-drug interactions with PUR1900, potentially making it a safer alternative to oral itraconazole therapy for ABPA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary
Pulmatrix, Inc. announces Q2 2023 financial results and corporate update. Enrollment for Phase 2b study of PUR1900 ongoing with 13 active sites. IND submitted for Phase 2 study of PUR3100 for Acute Migraine. $25.8 million in cash and cash equivalents at end of Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
earnings
Rhea-AI Summary
Pulmatrix has submitted an IND application to the FDA for PUR3100, an inhaled dry powder formulation of dihydroergotamine (DHE) to treat acute migraine. The Phase 1 study showed that PUR3100 had similar pharmacokinetics to IV DHE with fewer side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
earnings
Pulmatrix Inc

Nasdaq:PULM

PULM Rankings

PULM Stock Data

5.92M
3.65M
0%
8.59%
0.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Lexington

About PULM

pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.